Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study

Pyrotinib is an irreversible pan-ErbB inhibitor targeting epidermal growth factor receptor, human epidermal growth factor receptor 2 (HER2), and HER4. This randomized, double-blinded phase 3 study evaluated the efficacy and safety of pyrotinib plus capecitabine for HER2-positive local relapsed or metastatic breast cancer.

Read More>>

Breast cancer patients with low estrogen receptor expression gain no significant survival benefit from endocrine therapy: a real-world study from China

Rates of patients receiving endocrine therapy. (A) The annual rate of patients receiving endocrine therapy, and (B) the association between the rate of patients who received endocrine therapy and ER expression levels. ER, estrogen receptor.

Read More>>

Analysis of tumor heterogeneity at the molecular level: a case report of efficacy separation in metastatic breast cancer

Although breast cancer frequently metastasizes to the lungs, rarely breast cancer patients develop separation of the efficacy of different lesions in pulmonary metastases. Differentiation at genetic level between drug-resistant lesion and sensitive lesion may be very challenging but is essential for prognostic and therapeutic considerations.

Read More>>

An advanced refractory breast cancer patient with human epidermal growth factor receptor 2 discordance: a case report

Computed tomography (CT) scan of previous metastases. (A) A metastatic site on the right chest wall was detected (red arrow) in December 2016; (B) the size of the metastasis was found to decrease after treatment with lapatinib plus capecitabine (red arrow). The effectiveness was evaluated as partial response according to the RECIST 1.1 system; (C) the metastatic site on the right chest wall was observed to have increased in size again in February, 2018 (red arrow); (D) a new metastatic site on the right chest wall was discovered in September, 2018 (red arrow), marking the failure of the second-line therapy.

Read More>>

Pyrotinib: a new promising targeted agent for human epidermal growth factor receptor 2-positive breast cancer

Among the different TKIs, in addition to lapatinib, also neratinib and tucatinib have been recently approved by the Food and Drug Administration (FDA) thus becoming two new available targeted treatment options for patients with HER2-positive metastatic breast cancer.

Read More>>

How to optimize real-world study: concept, opportunities, and evidence quality

World Health Statistics 2020 has indicated that, although both life expectancy and healthy life expectancy have increased 8% between 2000 and 2016, non-communicable diseases, which account for 71% of all global deaths, remain a considerable health burden. As an example, breast cancer, the most common cause of cancer deaths among females in 2017, was also responsible for an estimated 626,679 deaths globally in 2018.

Read More>>

AME entered an official partnership with Publons to enhance wide-ranging recognition for reviewers

AME Publishing Company entered an official partnership with Publons, a product of Clarivate Analytic Company (which owns Web of Science, EndNote, ScholarOne, among many others), as of April 2020. Around 60 AME journals’ peer review systems are now integrated seamlessly into the Publons platform (https://publons.com/about/home). The partnership was done to recognize our expert peer reviewers spontaneously for their review contribution.

Read More>>

Editor-in-Chief of TBCR

Dr. Prof. Zefei Jiang, MD, is a Medical Professor of PLA General Hospital, and a supervisor of oncology doctoral candidates.

Dr. Jiang graduated from the First Military Medical University in 1987 and started to work on the field of both clinic and scientific research of oncology. He currently serves as Vice director and Secretary-General of Chinese Society of Clinical Oncology, Chairman of Breast Cancer Expert Committee in Chinese Society of Clinical Oncology, Member of St. Gallen International Consensus of Breast Cancer Experts, Chairman of Breast Disease Branch of Beijing Medical Association.

Read More>>